RT Journal Article SR Electronic T1 Platelet findings in 22q11.2 Deletion Syndrome correlate with disease manifestations but do not correlate with GP1b surface expression JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.06.10.22276258 DO 10.1101/2022.06.10.22276258 A1 Campbell, Ian M. A1 Crowley, T. Blaine A1 Jobaliya, Chintan A1 Bailey, Alice A1 McGinn, Daniel E. A1 Gaiser, Kimberly A1 Bassett, Anne A1 Gur, Raquel E. A1 Morrow, Bernice A1 Emanuel, Beverly S. A1 Franco, Aime T. A1 French, Deborah A1 Zackai, Elaine H. A1 McDonald-McGinn, Donna M. A1 Lambert, Michele P. YR 2022 UL http://medrxiv.org/content/early/2022/06/14/2022.06.10.22276258.abstract AB Prior studies have demonstrated that patients with chromosome 22q11.2 deletion syndrome (22q11.2DS) have lower platelet counts (PC) compared to non-deleted populations. They also have an increased mean platelet volume. The mechanism for this has been postulated to be haploinsufficiency of the GPIBB gene. We examined platelet parameters, deletion size and factors known to influence counts, including status of thyroid hormone and CHD, in a population of 825 patients with 22q11.2DS. We also measured surface expression of GPIB-IX complex by flow cytometry. The major determinant of PC was deletion status of GP1BB, regardless of surface expression or other factors. Patients with nested distal chromosome 22q11.2 deletions (those with GP1BB present) had higher PCs than those with proximal deletions where GP1BB is deleted. Patients with 22q11.2DS also demonstrated an accelerated PC decrease with age, occurring in childhood. These data demonstrate that genes within the proximal deletion segment drive PC differences in 22q11.2DS and suggest that PC reference ranges may need to be adjusted for age and deletion size in 22q11.2DS populations. Bleeding did not correlate with either platelet count or GP1b expression. Further studies into drivers of expression of GP1b and associations with severe thrombocytopenia and immune thrombocytopenia are needed to inform clinical care.Competing Interest StatementD.M.M-M. serves as a Trustee for the 22q11.2 Society. M.P.L. is a consultant for Novartis, Dynamed (EBESCO), Octapharma, Sysmex, CSL Behring, Dova, Shionogi, Sobi, Bayer, and the Department of Justice. She is a member of an advisory board for Novartis, Rigel, Dova, Principia, and Argenx. She has received research funding from OctaPharma, Sobi, Janssen, Argenx, Dova, Principia, Novartis, Astra Zeneca, Quansys, and Sysmex but there is no clear way that any of these organizations would gain or lose financially though this publication. She serves as a medical advisor for the Platelet Disorder Support Association, the 22q11.2 Society, and the Cornelia de Lange Syndrome Foundation. The remaining authors declare no conflicts of interest. Funding StatementThis study was funded by the NIH: UO1MH191739, U01MH087636, PO1HD070454.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at the Children's Hospital of Philadelphia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCardiac phenotype and sequencing data are publicly available in dbGaP: Data dictionaries and variable summaries are available on the dbGaP FTP site: (ftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001339/phs001339.v1.p1), while the public summary-level phenotype data may be browsed at: (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001339.v1.p1). Whole genome sequencing data is available through the International Brain and Behavior Consortium (http://www.22q11-ibbc.org). De-identified laboratory data is available upon request from D.M.M.-M. ftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001339/phs001339.v1.p1 https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001339.v1.p1)